Audit: QRS - Rooibos for Health & Longevity
Audit conducted on 21/08/2026 01:18 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 85 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Protocol, time-to-effect, benefit/risk headings, gates, monitoring table and qualitative items all trace to ER lines 281–305, 323–341, 373, 399–420. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “unproven in humans”, “unsupported in human trials”, “no trial has confirmed” carried across from the ER monitoring table. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications remain absolute; the conflicted glucose finding is reported as “absent in people studied”, matching ER line 440. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Gates draw only from Key Interactions & Contraindications; no Benefit- or Risk-Modifying Factor appears anywhere on the sheet. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, author names, NCT identifiers or brand names (e.g. Afriplex GRT) appear in the QRS at all. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | Examine’s dosing note (ER line 333) is carried as an unattributed fact; no new attribution is added. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Sceptical, magnitude-first register of the ER Conclusion is preserved. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets in Monitoring paired with plain-language At-A-Glance. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Protocol cells describe what was studied (“Measured after six weeks of six cups daily”) rather than instructing. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Cadence text is nominal (“liver panel repeated at 12 weeks”), not imperative as in ER line 397. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommended”, “should”, or “advised” in the QRS’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the sheet. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Biomarker names carry their abbreviations in parentheses; jargon retained (CYP3A4) is the ER’s own bold label required verbatim by 4.2. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Benefits and Risks are heading-only lists; gate items are stripped to the key fact. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed; no direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Ten-marker monitoring panel with optimal functional ranges assumes a proactive, self-tracking reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Six cups daily and a baseline/12-week liver panel are presented without hedging on effort. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Functional ranges tighter than conventional cut-offs are used throughout, not population reference ranges. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-A-Glance separates the reliable caffeine/iron property from the single-study findings, matching the ER’s audience-differentiated conclusion. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “Longevity” appears in the title; “anti-aging” appears nowhere. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal terms used throughout (“alanine aminotransferase”, “non-steroidal anti-inflammatory drugs”); plain-language wording is confined to At-A-Glance, where item 7.4 requires it. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed strings verified byte-identical to [qrs_template] (lines 446, 492, 536, 567, 584, 622, 649, 653–655, 806). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Every template variable present; the repeatable marker_#_* and qualitative_item_# spans are expanded to marker_1–10 and qualitative_item_1–4. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Structural diff against the template shows no change outside variable spans; website="evidence_review", website="audit" and website="full_review" spans are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section is empty; the absent Benefits-High and Risks-High/Medium tiers are governed by items 12.5 and 13.5 instead. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Standard intake”, “Split versus single dose”, “Extract alternative” and all eight Key Interaction labels are verbatim from ER lines 281–295 and 323–333. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Marker names and benefit/risk headings are verbatim; the Time-to-Effect cell labels derive from ER line 373, which carries no bold sub-labels to copy. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | The ER’s tier emoji and the “⚠️ Conflicted” markers on Blood Glucose Lowering and Idiosyncratic Drug-Induced Liver Injury are stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed rather than extended: Benefits and Risks carry ER headings only, gate items are stripped to the key fact, and no ER “Magnitude” paragraph is reproduced. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after <!doctype html> on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- line 3, closing --- line 13; the descriptive text on line 2 precedes the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no element repeats its values. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, and it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: rooibos_2026-0825-2328_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0821-0047. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file on disk: rooibos_2026-0825-2328_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Rooibos for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Rooibos for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “08/21/2026”, matching qrs_creation_date 2026-0821-0047. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only title and the template subline; the ER’s “Also known as” line is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER lines 440–444, leading with the intake level that produced the effects. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 58 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Caffeine-free/unusual chemistry (line 440), fat-oxidation and glutathione shift (line 440), iron/caffeine advantage (line 440), single-study findings and absent glucose effect (line 440). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | “plant compounds” for polyphenols, “blood-fat”, “stress-hormone”, “heart-muscle”; no acronyms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | Refers only to “single small studies”; no trial is named. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No figures, percentages, or confidence intervals. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from “Populations who should avoid Rooibos”, ER lines 297–305. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All four ER avoid-populations are present, one-to-one. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 570–579: four <li> elements inside the span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | “until the cause is established”, “rather than brewed tea” and “given unresolved estrogenic activity in isolated compounds” are all stripped. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(typical target trough 5–15 ng/mL)” preserved; the ALT threshold is kept as “above 3× the upper limit of normal”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s avoid-population bullets contain no ranking notation. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names four avoid-populations and the section is correspondingly populated. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from ER lines 281–295. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All eight ER interaction bullets carried; none duplicates an avoid-population entry. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 587–612: eight <li> elements inside the span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every “Severity / Consequence / Mitigation” clause is stripped; only label plus drug list remains. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Drug lists retained and trimmed within the allowance (diclofenac, beetroot nitrate and chromium dropped from three-item lists; no list dropped entirely). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER interaction bullets contain no ranking notation. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names eight such bullets and the section is correspondingly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Drawn from Therapeutic Protocol, ER lines 321–343. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Standard intake, split-versus-single dosing, and the extract alternative — the only three bullets that specify what to take, how much, and how often. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies more than three actionable aspects; no set is unused. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine cells populated from ER lines 323, 325, 329 and 333. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Six weeks for lipid/oxidative markers, twelve weeks for heart-muscle mass, under one hour for enzyme inhibition — the three intervals given at ER line 373. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Leads with the Medium-tier oxidative/lipid benefit, then the ~6% left-ventricular-mass reduction, then the transient enzyme effect for which no effect size is reported. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects are present in the ER; no set is unused. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine cells populated; the “nothing is perceptible subjectively” note is carried verbatim from ER line 373. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information at line 373. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Drawn from ER lines 129–201. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 538, 541, 547, 554. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Only the ER’s benefit headings appear; every “Magnitude” paragraph is dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives; the “⚠️ Conflicted” marker on Blood Glucose Lowering is removed. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER has no High-tier benefit; line 538 carries style="display: none" with no empty-state text. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Drawn from ER lines 217–265. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 624, 627, 630, 638. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Only the ER’s risk headings appear; every “Magnitude” paragraph is dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives; the “⚠️ Conflicted” marker on Idiosyncratic Drug-Induced Liver Injury is removed. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER has no High- or Medium-tier risk; lines 624 and 627 both carry style="display: none" with no empty-state text. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Drawn from Monitoring Protocol & Defining Success, ER lines 395–410. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All ten ER table rows (ALT, AST, GGT, LDL-C, triglycerides, HDL-C, hs-CRP, ferritin, HbA1c, home blood pressure) appear with their optimal functional ranges intact. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 795–800 carry baseline, 12-week liver panel, six-to-twelve-month repeats, and the two-week check for tacrolimus/warfarin/sulfonylurea, matching ER line 397. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Drawn from the qualitative-marker list at ER lines 412–420. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All four ER qualitative markers present: evening calm/sleep onset, digestive comfort, daytime energy stability, and the hepatic warning signs. |
Issues 21/08/2026 01:18
Pass rate 100.00%. No issues found.
Issues 21/08/2026 01:08
- 4.5 — Sections not condensed to budget: The ten Monitoring “Why” cells (lines 668–790) reproduce the ER’s full “Why Measure It?” sentences verbatim, the four Qualitative Assessment items (lines 811–831) reproduce near-complete ER sentences, and the “Supplements with additive effects” caution item (lines 605–609) carries a doubled example list; together these push the sheet past the one-A4-page budget instead of being condensed to cell-sized entries.
Fixes 21/08/2026 01:08
- 4.5 — Monitoring “Why” cells condensed: Shortened seven of the ten
marker_#_whycells from full ER sentences to cell-sized entries (e.g., “The angiotensin-converting enzyme finding predicts a fall that no trial has confirmed” to “The enzyme finding predicts a fall no trial has confirmed”; “Confirms rooibos is not costing iron status the way ordinary tea does” to “Confirms no cost to iron status, unlike ordinary tea”). - 4.5 — Qualitative items condensed: Trimmed
qualitative_item_1toqualitative_item_3to their key facts (e.g., “Digestive comfort, since traditional use centres on gastrointestinal settling” to “Digestive comfort, the centre of traditional use”); the liver-warning item was left intact. - 4.5 — Caution example lists trimmed: Reduced the example lists in the “Supplements with additive effects” and “Over-the-counter medications” interaction items to two named examples per class, preserving each drug class and its qualifier as required by 9.5.
Issues 21/08/2026 01:00
- 12.4 / 13.4 — Conflicted qualifier kept in parens: The tier lists retain the parenthetical “(conflicted)” on “Blood Glucose Lowering” (
benefits_low, line 551) and on “Idiosyncratic Drug-Induced Liver Injury” (risks_low, line 633), whereas sections 12 and 13 require parenthetical qualifiers to be stripped because the tier already encodes evidence strength.
Fixes 21/08/2026 01:00
- 12.4 / 13.4 — Conflicted qualifier stripped: Removed the parenthetical “(conflicted)” from “Blood Glucose Lowering” in
benefits_lowand from “Idiosyncratic Drug-Induced Liver Injury” inrisks_low, leaving the bare ER headings so the tier alone carries the evidence-strength signal.
Issues 21/08/2026 00:53
- 9.5 — Dropped parenthetical drug synonym: The Key Interactions item at QRS line 598 reads “paracetamol”, dropping the ER’s parenthetical synonym in “Paracetamol (acetaminophen)” (ER line 289), which 9.5 requires be preserved rather than dropped entirely.
Fixes 21/08/2026 00:53
- 9.5 — Restored paracetamol synonym: The Over-the-counter medications interaction item now reads “paracetamol (acetaminophen)” instead of “paracetamol”, restoring the ER’s parenthetical synonym.